GSK to buy liver disease drug from Boston Pharmaceuticals for up to $2 billion
GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includes an upfront payment of $1.2 billion and milestone payments. Efimosfermin, targeting steatotic liver disease and MASH, is expected to launch in 2029, with (...)
Site référencé: The Economic Times
The Economic Times
Wall Street Week Ahead-Fed outlook in focus as US stocks rally picks up steam
3/05/2025
IndusInd Bank brings Cyril Mangaldas for legal heft
3/05/2025
Rupee hits a 6-month high at 83.78/$, erases 2025 losses
3/05/2025
JSW Steel-Bhushan Power fallout : In the absence of legal certainty, foreign investors may shun stressed assets
3/05/2025
Door knocks and DNA tests : How Trump administration plans to keep tabs on 450,000 migrant kids
2/05/2025
Drones bomb aid ship bound for Gaza ; NGO blames Israel
2/05/2025
